12:00 AM
 | 
Mar 02, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Silenor doxepin regulatory update

Somaxon received a complete response letter from FDA for an NDA for Silenor doxepin to treat insomnia. The company said FDA raised issues regarding the interpretation of efficacy data and asked the...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >